ITM 54th Annual Colloquium

Theme 3:

Drug resistance

Dr. Coralith Garcia

Dr. Coralith Garcia is an infectious diseases and tropical medicine doctor. She has a master degree in clinical epidemiology. She did her under- and post-graduate studies in Universidad Peruana Cayetano Heredia (UPCH), Lima, Peru.

Currently, she is an attending physician of the Department of Tropical Medicine and Infectious Diseases of Cayetano Heredia Hospital. She is also a professor of the UPCH Medical School and a member of the Institute of Tropical Medicine Alexander von Humboldt-UPCH.

Her research is focused on antimicrobial resistance of key nosocomial pathogens.

Picture of Coralith Garcia

Prof. Dr. Jean-Claude Dujardin

Prof. Jean-Claude Dujardin is a Doctor in Science (Zoology), head of the Unit of Molecular Parasitology (ITM) since 2002 and head of the Department of Biomedical Sciences (ITM) since 2011.

He explored the diversity of Leishmania and leishmaniases for over 25 years, ‘from genomes to eco-systems’. He lead several international consortia on drug resistance, which provided him an holistic perception of this phenomenon.

In his presentation, he will highlight the unique nature of antimony resistance in L. donovani and its potential impact for new drugs.

Picture of JC Dujardin

Dr. Didier Ménard

P. falciparum artemisinin resistance: a quiescent strategy ? 

International Network of Pasteur Institutes - Senior Researcher Head of the Malaria Molecular Epidemiology Unit - Pasteur Institute of Cambodia.

Dr. Menard’s main research projects conducted since 2003 are aimed at improving our knowledge of the malaria situation (infection and disease), at assessing tools used to control and/or eliminate this disease in particular with regard to polymorphisms of the local parasite populations and at developing improved assessment tools.

Currently, as the head of the Malaria Molecular Epidemiology Unit at Pasteur Institute in Cambodia (IPC), research project areas are focussed on:

  • Supporting and evaluating the impact of the strategies implemented by MOH and developing tools and strategies that will replace passive surveillance of morbidity.
  • Conduct research focused on P. falciparum artemisinin resistance for monitoring the declining efficacy of artemisinins.
  • P. vivax malaria challenges & other emerging Plasmodium sp.
Picture of Didier Menard

Prof. Sébastien Gagneux

The evolution of multidrug-resistant tuberculosis

Sébastien Gagneux is Unit Head and Assistant Professor at the Swiss Tropical and Public Health Institute (Swiss TPH) & University of Basel, Switzerland. Dr. Gagneux received his PhD from the University of Basel and worked as a postdoctoral fellow at Stanford University and the Institute for Systems Biology in Seattle. He spent three years as a Program Leader at the MRC National Institute for Medical Research in London, UK before joining Swiss TPH.

Dr. Gagneux studies the cause and consequence of genetic diversity in Mycobacterium tuberculosis. This comprises evaluating the effect of bacterial genetics on the fitness of drug-resistant M. tuberculosis, and studying the phylogeography and population genomics of M. tuberculosis and its relevance for host-pathogen interaction.

Picture of Didier Menard

Dr. Kevin Ariën

Resistance induction as a tool to study compound-pathogen interactions

Kevin Ariën graduated as a Master in Biomedical Sciences from the Vrije Universiteit Brussel (VUB) in 2001. For his thesis research, he worked on Theileria parva at the Department of Animal Health of the Institute of Tropical Medicine, Antwerp, Belgium (ITM).

Beginning 2002, Kevin started his PhD research in the lab of Prof. Dr. Guido Vanham at the Department of Microbiology of the ITM. In 2002, 2003 and 2005 he spent several months in the research lab of Prof. Dr. Eric J. Arts at the Case Western Reserve University, Cleveland, USA, where he studied the replicative fitness of HIV-1 and HIV-2 viruses.

Kevin obtained his PhD in 2005 from the Universiteit Antwerpen (UA) on HIV replicative fitness. After a short intermezzo in pharmaceutical industry (Tibotec-Virco, Mechelen, Belgium), he started postdoctoral research in 2006 in the lab of Prof. Dr. Bruno Verhasselt at the Universiteit Gent, studying various molecular and immunological aspects of the HIV accessory protein Nef. During this time, Kevin was granted a postdoctoral fellowship of the Research Foundation-Flanders (FWO). At the end of 2009, Kevin returned to the ITM to study mechanisms of HIV sexual transmission and microbicides.

Picture of Kevin Ariën